Thymosin beta-4 protected brain cells from prion protein-induced neurotoxicity by activating autophagy and maintaining cholinergic signaling — effects reversed when autophagy was blocked.
Neuroprotection via autophagyThymosin beta-4 activated LC3A/B and Beclin1 autophagy markers to protect brain cells from prion toxicity while maintaining cholinergic signaling
What the researchers found
In HT22 mouse hippocampal cells treated with toxic prion peptide PrP (106-126):
- Tβ4 increased autophagy markers LC3A/B and Beclin1, protecting against prion-induced neurotoxicity
- Tβ4 maintained balance between autophagy markers and AKT/mTOR pathway factors competitively against prion effects
- Cholinergic signaling markers (ChTp and AChE) were preserved by Tβ4 against prion-induced disruption
- All protective effects were reversed by 3-MA (autophagy inhibitor), confirming autophagy as the mechanism
- Results demonstrate Tβ4 maintains cholinergic signaling through autophagy induction
Why it matters
Prion diseases have no effective treatment, and the cholinergic system is also damaged in Alzheimer's disease. Finding that a naturally occurring peptide can protect brain cells by activating cellular self-cleaning and preserving key brain signaling pathways opens potential therapeutic avenues for multiple neurodegenerative diseases, not just prion disease.
How the study worked
HT22 mouse hippocampal cells were treated with the toxic prion peptide fragment PrP (106-126) with and without thymosin beta-4. Autophagy markers (LC3A/B, Beclin1), autophagy pathway proteins (AKT, p-AKT, mTOR, p-mTOR), and cholinergic signaling markers (ChTp, AChE) were measured. The autophagy inhibitor 3-MA was used to confirm the mechanism. Protein expression was assessed by Western blot.
What this study cannot tell us
This was an in vitro study using a single mouse hippocampal cell line (HT22), which may not reflect the complexity of prion disease in the living brain. The prion peptide fragment PrP (106-126) is a model of prion toxicity but may not capture all aspects of actual prion disease. Concentrations used in cell culture may not correspond to achievable tissue levels in vivo. No animal model of prion disease was tested.
How to read the evidence
This is an in vitro cell culture study using a mouse hippocampal cell line. While it provides clear mechanistic evidence, no in vivo animal or human data exists for this application.
When this study was published
Published in 2019, this adds to the growing evidence for thymosin beta-4's neuroprotective properties across various models of brain injury and disease.
The bigger picture
Thymosin beta-4 continues to show neuroprotective potential across multiple disease models. This study adds prion disease to its therapeutic scope and identifies autophagy as a key mechanism. Since impaired autophagy is implicated in many neurodegenerative diseases (Alzheimer's, Parkinson's, Huntington's), Tβ4's ability to activate this pathway could have broad applications.
Questions still open
- Does thymosin beta-4 show neuroprotective effects in animal models of prion disease?
- Could Tβ4's autophagy-activating properties benefit other neurodegenerative diseases like Alzheimer's or Parkinson's?
- What is the optimal dosing strategy for Tβ4 to achieve therapeutic autophagy levels in the brain?
Common questions
What is thymosin beta-4 and how does it protect the brain?
What are prion diseases?
Read the original research
Thymosin beta 4-Induced Autophagy Increases Cholinergic Signaling in PrP (106-126)-Treated HT22 Cells.
Neurotoxicity research, 36(1), 58-65
Citation
Han, Hye-Ju; Kim, Sokho; Kwon, Jungkee. (2019). Thymosin beta 4-Induced Autophagy Increases Cholinergic Signaling in PrP (106-126)-Treated HT22 Cells.. Neurotoxicity research, 36(1), 58-65. https://doi.org/10.1007/s12640-018-9985-0